NCT06255028View on ClinicalTrials.gov

A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 6, 2025

Primary Completion Date

August 31, 2028

Study Completion Date

August 31, 2028

Conditions
Systemic Lupus ErythematosusLupus NephritisIdiopathic Inflammatory MyopathiesDiffuse Cutaneous Systemic Sclerosis
Interventions
BIOLOGICAL

CNTY-101

CNTY-101 cells for intravenous (IV) infusion

BIOLOGICAL

IL-2

IL-2 subcutaneous (SC) injection

DRUG

Lymphodepleting Chemotherapy

LDC as prespecified in the protocol.

Trial Locations (6)

60611

RECRUITING

Lurie Children's; Northwestern Medicine - Northwestern Medical Group, Chicago

77030

RECRUITING

Texas Children's Hospital, Houston

84113

RECRUITING

Primary Children's Hospital, Salt Lake City

90033

RECRUITING

Keck School of Medicine of University of Southern California, Los Angeles

98109

RECRUITING

Fred Hutch, Seattle

957817

RECRUITING

UC Davis, Sacramento

Sponsors
All Listed Sponsors
lead

Century Therapeutics, Inc.

INDUSTRY